

## **Declaration of Competing Interest**

The authors declare competing financial interests.

R.M. and C.A.Z. are listed as coinventors on a patent for the use of (2R,6R)-HNK, and other hydroxynorketamines in the treatment of depression.

C.A.Z, R.M, T.G., C.T., P.Z., and P.M are listed as coinventors on a patent application for the use of (2R,6R)-HNK and (2S,6S)-HNK in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorder.

C.A.Z, R.M, T.G., C.T., P.Z., and P.M are listed as coinventors on a patent application for the crystal forms and synthesis of (2R,6R)-hydroxynorketamine and (2S,6S)-hydroxynorketamine.

C.T. and P.M. are listed as coinventors on a patent application for the synthesis and purification of (2R,6R)-hydroxynorketamine.

## **Acknowledgements**

This work was supported by the Division of Preclinical Innovation, National Center for Advancing Translational Sciences and the Center for Cancer Research, National Cancer Institute and the Intramural Research Programs of the National Institute of Mental Health and the National Institute of Aging. This article reflects the views of the author and should not be construed to represent FDA's views or policies. The authors would like to thank Steve Van Adestine (Covance Laboratories, Inc.) for assisting with image capture.